Why Is INJ Rising? Injective’s 28% Rally, U.S. Policy Talks and Tokenization Explained

Reporting date: October 16, 2026. Market-data cutoff: approximately 08:15 UTC on October 16. This is the time I checked the accessible CoinMarketCap page, not an exchange-level trade timestamp. Rolling 24-hour readings can change quickly.

INJ is rallying as Injective draws attention to reported discussions with U.S. policymakers about tokenization and on-chain finance. At my October 16 check, CoinMarketCap showed INJ at $9.27, up 28.25% over 24 hours. The move is clear; its cause is less certain. I see a fresh policy narrative built on earlier infrastructure announcements, not evidence of a new U.S. government endorsement.

Why is INJ rising now?

The immediate news is Injective’s account of its leadership engaging with U.S. policymakers. Contemporaneous reporting describes a project social-media post about CEO Eric Chen speaking with representatives associated with the White House, Securities and Exchange Commission (SEC) and Commodity Futures Trading Commission (CFTC). The linked Injective announcement dates to the October 15 news cycle, but its original text was not directly accessible during this review.

That announcement arrived while INJ was attracting more trading interest. CoinMarketCap’s accessible snapshot shows a substantial 24-hour gain and elevated reported turnover. Yet an announcement and a price increase appearing close together do not establish that the first caused all of the second. Positioning, thin order books and sector sentiment could also matter, and I do not have matching derivatives or execution data to apportion the move.

The timeline matters more than a list of bullish headlines:

Date	Development	What changed
January 20, 2026	Injective announced approval of governance proposal IIP-617	An earlier plan to tighten INJ issuance; not new this week.
July 16, 2026	Injective Mint introduced	Issuance and compliance-control software announced in private beta.
July 27, 2026	POSCO International described a completed proof of concept	Real trade data tested; a broader operational rollout was still a future step.
August 19, 2026	Injective said Injective Institutional Services had effective SEC transfer-agent registration	An affiliated entity’s claimed regulated recordkeeping capability, not SEC approval of INJ.
September 4, 2026	Injective described Pineapple Financial’s mortgage-record migration	Reported digitization of existing mortgage records, not the issuance of $1 billion of new securities.
October 15–16, 2026	Injective’s U.S. policy-meetings story circulated; INJ rallied	Fresh public attention, with the exact meeting date and causal contribution not independently established.

For background on why the difference between a blockchain record and a financial instrument matters, see our earlier CryptoLinks reporting on tokenization and market infrastructure.

What did Injective’s U.S. meetings actually establish?

Injective identifies Eric Chen as its CEO. Its reported statement says he met policymakers associated with the White House, SEC and CFTC to discuss advancing tokenization and on-chain finance. What I can verify from accessible reporting is that Injective made that claim and news outlets repeated it. I could not independently establish the precise meeting date, venue, names of individual attendees or a jointly announced outcome. Some reports describe Wednesday, October 14; others refer to October 15.

That distinction is important. Meeting a White House-associated official does not mean meeting the president or visiting the White House building. Speaking to regulators is not a government partnership, procurement contract, rulemaking decision, exemption or endorsement.

There is an earlier, separate piece of official evidence: the SEC logged a January 13, 2026 meeting with representatives of Injective Labs, Injective LLC and the Injective Foundation. That public record demonstrates prior engagement, but it does not verify what happened during the newly reported October conversations.

My reading is that policy access can make a financial-infrastructure story more visible. The development becomes materially stronger only when a regulator publishes a relevant record, an issuer announces a real deployment, or customers show sustained usage.

Did the SEC approve Injective or INJ?

No such approval follows from the information reviewed here. In its August 19 announcement, Injective said Injective Institutional Services was registered and effective as a transfer agent. Separate secondary reporting identifies the affiliated legal entity as Injective Institutional Services, LLC, but I could not independently confirm the complete SEC registration record. I could confirm the company announcement and secondary reporting, but not the entity’s Form TA-1 registration record, definitive effective date or current status in an accessible primary SEC registrant record. Those details need a final pre-publication check.

A transfer agent maintains securityholder records and processes changes to ownership. It is an important, specific market function—not a blanket license for a blockchain. SEC staff guidance on distributed ledgers says a registered transfer agent may use blockchain technology for its official master securityholder file, provided recordkeeping, safeguarding and other federal requirements are met. The SEC expressly describes this as staff guidance, not a new Commission approval of a particular project.

The August announcement therefore should not be confused with SEC approval of the INJ token, permission for every tokenized asset on Injective, broker-dealer or exchange authorization, or approval of an INJ exchange-traded fund. For a broader explanation of the rules, CryptoLinks maintains a cryptocurrency regulation resource section.

The tokenization work behind the rally

This is where I find a more useful test of Injective’s narrative. The project has described actual tools and commercial experiments, but they are at different stages and do not produce interchangeable dollar figures.

Initiative	What the evidence supports	What it does not prove
Injective Mint — July 16	Injective said its no-code asset-issuance platform was live in private beta, with holder restrictions, jurisdiction controls, freezes, pauses and separated administrative permissions. Source.	Open public availability, regulatory compliance of every asset, or significant recurring fee revenue.
POSCO International and LG CNS — July 27	POSCO’s own newsroom confirmed a completed proof of concept using real trade data to test shared records, tokenized receivables and automated documentation, with Injective used for the receivables framework.	A completed enterprise-wide rollout, a liquid market for receivables, or published production volumes.
Pineapple Financial — September 4	Injective reported more than $1 billion of mortgage records represented on-chain and cited 2,079 records at that time, against a longer-term goal involving more than 29,000 mortgages. The Pineapple product site describes digitized mortgage data.	$1 billion in new investment, mortgage-backed securities issued, blockchain total value locked (TVL), sales, revenue or INJ buying of the same value.

The Pineapple distinction is particularly easy to miss. An on-chain record linked to an existing loan can improve provenance and verification without transferring the legal mortgage, creating a tradable security or adding fresh capital. I would not add the notional values of mortgage records and trade receivables into a single “tokenized assets” total.

For a practical introduction to this infrastructure, readers can use our DeFi and tokenization guide, while the CryptoLinks Layer 1 blockchain directory provides broader network context.

Does the market data support the rally?

The accessible market snapshot supports a sharp price move and substantial trading activity. It does not, on its own, identify who bought, why they bought or whether the rally will last.

Metric	Observation	Window / source	Limitation
INJ price and return	$9.27; +28.25%	Rolling 24 hours; CoinMarketCap, checked about 08:15 UTC, Oct. 16	Aggregated live page; no exchange-specific print timestamp.
Trading volume	$287.63 million	Reported 24-hour turnover on the same CoinMarketCap page	Aggregated volume is not proof of net buying or institutional participation.
Price range	$7.09–$9.31	CoinMarketCap 24-hour low and high at the same check	Not a calendar-day candle or verified support/resistance levels.
Exchange balances	1.26 million INJ on Aug. 12 versus 872,500 on Oct. 15, as reproduced in FXStreet reporting from Santiment	Roughly two months; secondary reproduction of Santiment data	I could not inspect Santiment’s underlying wallet labels, historical series or full methodology. This is not a measured 24-hour netflow.

A smaller balance on labeled exchange wallets can reflect withdrawals, staking, custody reshuffling, bridge movements or changes in wallet classification. It does not prove that investors bought new INJ, and a rising share of supply in profit can simply follow a rising price. Nor can exchange balances alone establish order-book depth.

I also could not establish a synchronized, auditable snapshot of INJ futures open interest, funding, liquidations or a BTC/ETH comparator at the exact same cutoff. That is why I am not calling this a short squeeze, institutional accumulation or a technically confirmed breakout. CoinMarketCap’s accessible primary trending table did not populate its rows, so I cannot independently certify a particular trending or top-gainer rank either.

Readers comparing providers can start with the CryptoLinks price-tracker directory and on-chain analytics tools directory rather than treating one dashboard as a complete explanation.

Can tokenization activity actually create demand for INJ?

INJ has network uses: transaction fees, proof-of-stake security, staking and governance. Injective also links some application revenue to its Community BuyBack mechanism, in which committed INJ is burned. Those are plausible economic connections between activity and the token. They do not mean every mortgage record or tokenized receivable forces an institution to buy an equivalent dollar amount of INJ.

The supply story needs care. Injective said IIP-617 was approved in January to tighten issuance alongside buybacks and burns. But lowering the rate of new issuance is not identical to shrinking total supply. Staking locks tokens for participation; it is not a permanent burn.

There is also a meaningful disclosure discrepancy. The October 16 CoinMarketCap page displays about 100 million INJ as total and maximum supply. Yet a September 2026 Canary Staked INJ ETF prospectus filed on SEC.gov says the initial supply was 100 million, the network has no fixed maximum, and total supply was 122,895,808 INJ as of September 15 after issuance and burns. That same issuer-filed prospectus reported a then-prevailing annual issuance rate of 4.40%. An issuer filing hosted by the SEC is not an SEC finding or an ETF approval, but this is a specific reason not to repeat “fixed supply” or “guaranteed deflation” uncritically.

In other words, the test is new issuance versus actual burns, tracked over time to determine the net change. I would want verified fee generation, transactions from real customers, consistent buyback execution and an explainable current circulating/total-supply methodology before assigning a lasting token-value effect to enterprise announcements. That same distinction between enterprise adoption and native-token value also shaped our earlier analysis of Quant’s tokenized-deposit rally.

What I would watch next

Signal	What is established now	What would strengthen the story	What it cannot establish alone
U.S. policy engagement	Injective has publicized reported discussions; the SEC also has an older, separate January meeting record.	A dated agency log, named participants, formal proposal or published next step.	Government backing or approval of INJ.
Enterprise adoption	POSCO completed a proof of concept; Injective Mint was announced in private beta; mortgage-record migration has been described.	Production deployments, verified asset/record counts, repeat users and paid transactions.	Automatic economic value accruing to INJ.
Spot market participation	CoinMarketCap reported strong rolling 24-hour volume alongside the rally.	Sustained spot turnover and liquidity after initial attention fades.	Long-term buyer identity or continued price gains.
Token economics	Earlier governance changes and buyback mechanisms are documented, but reported supply definitions conflict.	Auditable issuance, actual burns and reconciled on-chain supply by period.	A guaranteed net-supply decline or price floor.
Leverage and flows	Complete synchronized datasets were not available to this review.	Time-matched open interest, funding, liquidations, wallet-labeled netflows and order-book depth.	Causation from an isolated metric.

If spot activity persists and companies publish evidence of genuine production use, the rally may be reflecting more than a headline. If derivatives leverage rises faster than real spot participation while those milestones remain unconfirmed, the move could prove fragile. With the gaps in the data today, both interpretations remain open.

My conclusion is simple: the new item is the reported policy outreach; most of the infrastructure story predates it. INJ’s 28% snapshot is a market fact, but it is not evidence that Washington endorsed Injective or that tokenized mortgage records already create proportional INJ demand. The next credible catalyst would be something measurable—an official policy record, a production customer, or durable network economics—not another repetition of the same announcement.

For ongoing coverage and research tools, browse CryptoLinks News or the CryptoLinks homepage.

Disclosure: This is a reported market analysis, not investment advice. The first-person assessments above are editorial judgments based on public sources; they do not imply firsthand meetings, private access, trades or independent product testing. Market figures and regulatory claims should be rechecked before publication.